Effect of Niaspan on Cholesterol in Men

Completed

Conditions studied: HDL Cholesterol

In brief

To determine whether 8 weeks of Niaspan treatment increases cholesterol efflux in male subjects with low HDL-C cholesterol when compared to no treatment. To determine whether 8 weeks of Niaspan treatment increases fecal cholesterol excretion when compared to no treatment. To determine whether 8 weeks of Niaspan treatment increases the rate of global reverse cholesterol transport when compared to no treatment.

Key facts

Study ID

NCT00765284

Run by

KineMed

People needed

15

Starts

2007-12-01

Expected to finish

2011-06-01

Last updated by the study team

2011-06-30

Who can join

Age: 18 and older, up to 70. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Subjects meeting the following criteria at the Screening Visit will be eligible to participate:
• Provide written informed consent
• Male
• Age 18 to 70 years
• BMI 18.5-40 kg/m2
• HDL-C values <40 mg/dL
• Triglyceride value 150-500 mg/dL.
• Good health based on medical history, physical examination and laboratory safety tests performed at the screening visit or prior to initial dose of study medication.
• No clinically significant abnormality on ECG performed at the screening visit or prior to initial dose of study medication.
• Non-smoker and no other use of nicotine containing products for at least 6 months and does not plan to begin smoking during the course of the study.
• Dietary or nutritional remedies including plant sterol containing products (i.e. Benecol, SmartBalance, etc) of any sort for at least 2 weeks prior to and throughout the study.
• Willing to avoid the use of lipid modifying medications (excluding statins) such as the fibrates, cholestyramine, fish oil, and ezetimibe within 8 weeks prior to and during the study.
• Avoidance of extreme change of physical activity from screening through the follow-up period.

You may not qualify if…

• Subjects are excluded from participation in the study if any of the following criteria apply:
• History of intolerance to Niacin or Niaspan.
• Treatment with Niacin or Niaspan in the past 3 months (Multivitamin use with non-pharmacologic doses of Niacin - less than 500mg per day - is allowed).
• History of stroke, chronic seizures, or major neurological disorder.
• Significant emotional problems or a history of clinically significant psychiatric disorder.
• Bleeding diathesis or intolerance to aspirin.
• Anemia as defined as a hematocrit < 25%.
• History of gastritis, bleeding gastric or duodenal ulcers.
• History Type 1 or Type 2 diabetes, or fasting plasma glucose >125 mg/dL at screening or 75 gm OGTT with 2 hour glucose >140mg/dL.
• History of illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk through participation.
• History of ileal bypass, gastric bypass, or other condition associated with malabsorption.
• Abnormal thyroid function tests.
• AST or ALT > 1.5x the upper limit of normal.
• Active or recent gastrointestinal condition such as gastroenteritis, irritable bowel syndrome, chronic constipation, or diarrhea which may affect bowel movements.
• History of plant sterol storage disease or a history of intolerance to plant sterols or plant sterol containing products.
• History of neoplastic disease (i.e. leukemia, lymphoma, malignant melanoma), or myeloproliferative disease, regardless of the time since treatment. Exceptions include adequately treated non-melanomatous skin carcinoma, and other malignancies that may have been treated successfully >10 years prior to the screening visit with no evidence of recurrence.
• Excessive alcohol consumption defined as > three glasses of alcoholic beverages or distilled spirits per day. *** Must avoid excessive alcohol consumption throughout study.
• Currently using psyllium or other fiber based laxatives, phytosterol margarines, and/or over the counter (OTC) treatments that are known to affect serum lipids and has NOT been treated with a stable regimen for > 6 weeks prior to screening (Visit 1) or the subject DOES NOT agree to continue this regimen for the duration of the clinical trial.
• Regular user of illicit drugs or history of drug abuse (including alcohol) within the previous 2 years.
• Use of anabolic agents.
• Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject
• Use of any investigational drug within 30 days before screening

Where it is running

• Diabetes and Glandular Research Associates — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.